On September 16, 2022, the "ESG Forum for the Pharmaceutical and Healthcare Industry & Online Launch Meeting for the ESG Management Standards for the Pharmaceutical and Healthcare Industry", hosted by the China Chemical and Pharmaceutical Industry Association, was successfully held. This meeting brought together leading institutions and enterprises from China's economic, financial, and pharmaceutical and healthcare sectors, including the Financial Research Institute of the Development Research Center of the State Council and the Institute of World Economics and Politics of the Chinese Academy of Social Sciences. It aimed to facilitate in-depth exchanges on the ESG development experience in China's pharmaceutical industry and jointly build ESG risk management and disclosure standards with Chinese characteristics for the pharmaceutical and healthcare industry—the "ESG Management Standards for the Pharmaceutical and Healthcare Industry".

As a leading ESG enterprise in China's pharmaceutical industry, Sino Biopharm was invited to attend this meeting. During the meeting, it shared the Group's ESG development concept, work progress, and phased achievements, and expressed industry views on the ESG development prospects, challenges, and expectations of the pharmaceutical industry. At the same time, as one of the participating units in the formulation of the "ESG Management Standards for the Pharmaceutical and Healthcare Industry", Sino Biopharm, together with the China Chemical and Pharmaceutical Industry Association, launched the formulation work for the "ESG Management Standards for the Pharmaceutical and Healthcare Industry" at the meeting. In the future, Sino Biopharm will continue to combine its own ESG work experience to provide professional opinions and suggestions for the "ESG Management Standards for the Pharmaceutical and Healthcare Industry", contributing to the promotion of high-quality sustainable development in the pharmaceutical industry.

This invitation represents broad recognition from the industry and society for the company's continuous deep efforts in the ESG field. As a leading innovation and R&D-driven pharmaceutical group in China, the Group will always uphold the values of "benefiting the country, the people, and the enterprise". It will support the Healthy China strategy, seek health and well-being for more patients, and enable more diseases to be treated. At the same time, it will also remain committed to promoting the harmonious development of the company, employees, society, and the environment, and creating long-term value for itself and partners from all sectors.